- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company foc ...

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating G1 Therapeutics, Inc. (Nasdaq: GTHX), relating to its proposed merger with Kahn Swick & Foti, LLC ("KSF"). Under the terms of the proposal, KSF will commence a tender offer to purchase GT ...

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: G1 Therapeutics, Inc. (NASDAQ: GTHX)'s sale to Pharmacosmos A/S for $7.15 per share in cash. If you are a G1 shareholder, click here to learn more about your rights and options. PetIQ, Inc. (NASDAQ: PETQ)'s merger with Bansk Group for $31.00 per share. If you ...

MILWAUKEE, Aug. 7, 2024 /PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with Pharmacosmos. Click here to learn how to join our investigation https://www.ademilaw.com/case/g1-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. GI shareholders will receive only $7.15 per share in cash for a total equity value of approximately $405 million. The transaction agreem ...

G1 Therapeutics (NASDAQ:GTHX) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all outstanding shares of GTHX stock for $7.15 in cash. That represents a 68% premium to G1 Therapeutics' prior closing price. It's also a 133% premium to its 30-day volume weighted average price. This deal will have Pharmacosmos Group paying a total of $405 million for G1 Therapeutics. It's using current cash on hand and its e ...

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for ...

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for ...

RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes p ...

Company Overview - G1 Therapeutics (NASDAQ:GTHX) is positioned as a speculative but potentially rewarding investment in the small-molecule therapeutics sector, particularly in oncology [4][10][12] - The company currently has a market capitalization of less than $167 million, indicating a high-risk, high-reward profile [10] Valuation Metrics - G1 Therapeutics stock is trading at a trailing price-to-sales ratio of 1.96X, significantly lower than the sector average of 7.04X, suggesting it may be undervalued [6] - Projected revenue for G1 Therapeutics in 2024 is expected to decline to $72.29 million, a 12.4% decrease from $82.51 million in 2023, leading to a projected price-to-revenue ratio of approximately 2.3X [14] - Analysts forecast a recovery in fiscal 2025, with revenue potentially increasing to $93.82 million, representing a nearly 30% growth from 2024 projections [15] Market Growth Potential - The small-molecule drug market was valued at $42.01 billion in 2022 and is projected to reach $83.6 billion by 2030, indicating a compound annual growth rate (CAGR) of just under 9% [8] - Another report estimates the global small-molecule drug discovery market at $52.32 billion last year, with expectations to grow to $107.04 billion by 2032, reflecting a CAGR of 8.3% [16] Investor Sentiment - G1 Therapeutics stock experienced a nearly 25% increase in the week ending July 12, indicating positive investor sentiment and interest in the stock [9] - The stock is perceived as "cheap" at a closing price of $3.19 per share, which may attract retail investors despite the need for careful consideration of the context [13]

Financial Performance - G1 Therapeutics reported a revenue increase from $10.492 million in Q1 2023 to $14.079 million in Q1 2024, indicating strong growth [1] - The company also narrowed its net earnings loss from $27.595 million to $10.219 million during the same period, reflecting improved financial health [1] Clinical Trials and Developments - In May, G1 Therapeutics announced positive results from a clinical trial of trilaciclib for a specific type of breast cancer, which initially seemed promising [2] - However, the company later revealed that trilaciclib did not demonstrate a statistically significant treatment effect in certain breast cancer patients, leading to a disappointing outcome [13] - Following this setback, G1 Therapeutics plans to wind down the clinical trial related to trilaciclib [14] Market Reaction and Stock Performance - On June 24, G1 Therapeutics' stock experienced a significant drop of 41.1% due to the disappointing clinical trial results, highlighting the volatility associated with biotechnology stocks [3][5] - The company was recently added to the small-cap Russell 2000 and broad-market Russell 3000 indexes, which may attract index-fund investors [10] Future Focus - G1 Therapeutics is expected to shift its focus towards other potential treatments, including those for extensive-stage small cell lung cancer [4]